Eiger BioPharmaceuticals to Present at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual Conference

Rhea-AI Summary

Eiger BioPharmaceuticals, based in Palo Alto, California, announced that President and CEO David Cory will present a company overview at the H.C. Wainwright Third Annual Hepatitis B Virus Virtual Conference on October 18, 2022, at 3:00 PM ET. Investors can participate in one-on-one meetings at the conference. A live webcast of the presentation will be available on the company's website, with a replay accessible for at least 90 days. Eiger focuses on innovative therapies for hepatitis delta virus and has several programs designated as FDA Breakthrough Therapy.

PALO ALTO, Calif., Oct. 11, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that David Cory, President and CEO, will present a company overview at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual Conference on Tuesday, October 18, 2022 at 3:00 PM ET. The company will also host one-on-one meetings with investors at the conference.

A live webcast of the presentation will be available on the Investors section of the Eiger BioPharmaceuticals website at www.eigerbio.com, and a replay will be available on the website for at least 90 days. 

About Eiger

Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib/ritonavir for HDV, peginterferon lambda for HDV, avexitide for congenital hyperinsulinism, avexitide for post-bariatric hypoglycemia, and Zokinvy^® (lonafarnib) for progeria.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com 

Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-the-hc-wainwright-third-annual-hepatitis-b-virus-hbv-virtual-conference-301645595.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

What is Eiger BioPharmaceuticals presenting at the H.C. Wainwright conference?

Eiger BioPharmaceuticals will present a company overview at the H.C. Wainwright Third Annual Hepatitis B Virus Virtual Conference on October 18, 2022.

When is David Cory's presentation scheduled?

David Cory's presentation is scheduled for October 18, 2022, at 3:00 PM ET.

How can investors access the Eiger presentation?

Investors can access the presentation via a live webcast on Eiger's website, with a replay available for at least 90 days.

What is the stock symbol for Eiger BioPharmaceuticals?

The stock symbol for Eiger BioPharmaceuticals is EIGR.

What therapies does Eiger BioPharmaceuticals develop?

Eiger develops innovative therapies for hepatitis delta virus and other serious diseases, with several programs designated as FDA Breakthrough Therapy.